1. Khan O, Protheroe A. Testis cancer. Postgraduate Medical Journal.

2007 October;

83(984): 624-632.

2. Josephides E, Gala A, Chowdhury S. GPs have key role in managing men with

testicular cancer. Practitioner. 2014;258(1770):19-23.

3. Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. Journal

of Clinical Oncology. 2014 Oct 1;32(28):3085-92.

4. Fizazi K, Chen I ,Logothetis CJ. Germ-cell tumor survivors: the price for cure. Oxford

Journal. 2002;13(2):187-9.

5. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular

cancer. The Journal of Americal Medical Association. 2008 February; 299(6):672-84.

6. Horwich A, Nicol D, Huddart R. Testicular germ cell tumours. British Medical Journal.

2013 September 24:1-9.

7. Einhorn LH. Curing metastatic testicular cancer. Proceedings of the National Academy

of Sciences. 2002 April 2; 99(7):4592-95.

8. Stamberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G. Evaluation of long-

term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous

testicular cancer. Annals of Oncology. 2002;13 (2): 229-236.

9. Thibault, C., et al. Compliance with guidelines and correlation with outcome in patients

with advanced germ-cell tumours. Eur J Cancer, 2014. 50: 1284.

https://www.ncbi.nlm.nih.gov/pubmed/24560488

10. de Wit, R. Refining the optimal chemotherapy regimen in good prognosis germ cell

cancer: interpretation of the current body of knowledge. J Clin Oncol, 2007. 25: 4346.

https://www.ncbi.nlm.nih.gov/pubmed/17906198

11. Beyer, J., et al. [Chemotherapy for germ cell cancer]. Urologe A, 2004. 43: 1507.

https://www.ncbi.nlm.nih.gov/pubmed/15592707
12. Urology.jhu.edu [homepage on the internet]. Testis cancer. Baltimore: The James

Buchanan Brady Urological Institute [cited 2017 December 6] available from:

http://urology.jhu.edu/testis/testis_cancer_evaluation.php.

13. McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic Metastases from Pelvic Tumors:

Anatomic Classifi cation, Characterization and Staging. Radiology. 2014;254(1):31-46.

14. Brierley, J.E., et al., The TNM Classification of Malignant Tumours 8th edition. 2016.

http://www.uicc.org/resources/tnm/publications-resources

15. Peyret, C. Tumeurs du testicule. Synthèse et recommandations en onco-urologie.

[Testicular tumours. Summary of onco-urological recommendations] [Article in

French]. Prog Urol 1993. 2: 60. [No abstract available].

16. International Germ Cell Consensus Classification: a prognostic factor-based staging

system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative

Group. J Clin Oncol, 1997. 15: 594. https://www.ncbi.nlm.nih.gov/pubmed/9053482

17. Motzer, R.J., et al. Phase III randomized trial of conventional-dose chemotherapy with

or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as

first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin

Oncol, 2007. 25: 247. https://www.ncbi.nlm.nih.gov/pubmed/17235042

18. Fizazi, K., et al. Early predicted time to normalization of tumor markers predicts

outcome in poorprognosis nonseminomatous germ cell tumors. J Clin Oncol, 2004. 22:

3868. https://www.ncbi.nlm.nih.gov/pubmed/15302906

19. Fizazi, K., et al. Personalised chemotherapy based on tumour marker decline in poor

prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Lancet Oncol, 2014. 15:1442\\\